regadenoson Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
adenosine A receptor agonists	2362	313348-27-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: CVT-3146 rapiscan regadenoson lexiscan	Molecular weight: 390.36 Formula: C15H18N8O5 CLOGP: -2.86 LIPINSKI: 1 HAC: 13 HDO: 5 TPSA: 186.46 ALOGS: -1.91 ROTB: 4 Status: ONP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

Dose	Unit	Route
0.40	mg	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.05 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	65 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	7.48 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution)	0.94 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	7.30 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.70 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	2 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
April 10, 2008	FDA	ASTELLAS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Injection site extravasation	495.73	47.28	101	1843	6684	46677434
Infusion site extravasation	70.62	47.28	20	1924	5236	46678882
Unresponsive to stimuli	67.96	47.28	31	1913	32143	46651975
Nausea	67.07	47.28	109	1835	687345	45996773
Headache	57.89	47.28	84	1860	478268	46205850
Incorrect product administration duration	54.90	47.28	19	1925	9558	46674560
Extravasation	52.06	47.28	13	1931	2102	46682016
Tremor	51.97	47.28	41	1903	115598	46568520
Seizure	51.83	47.28	42	1902	123012	46561106
Chest pain	48.01	47.28	47	1897	176277	46507841

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Injection site extravasation	526.21	57.85	90	1259	2110	29949019
Cardiac arrest	86.68	57.85	53	1296	92797	29858332
Bradycardia	73.05	57.85	42	1307	65484	29885645
Incorrect product administration duration	70.19	57.85	19	1330	3903	29947226
Unresponsive to stimuli	68.32	57.85	30	1319	26389	29924740
Hypotension	67.52	57.85	62	1287	200503	29750626
Seizure	64.32	57.85	45	1304	98430	29852699

Pharmacologic Action:

Source	Code	Description
ATC	C01EB21	CARDIOVASCULAR SYSTEM CARDIAC THERAPY OTHER CARDIAC PREPARATIONS Other cardiac preparations
MeSH PA	D058908	Adenosine A2 Receptor Agonists
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D058913	Purinergic Agonists
MeSH PA	D058906	Purinergic P1 Receptor Agonists
FDA MoA	N0000175788	Adenosine Receptor Agonists
FDA EPC	N0000178375	Adenosine Receptor Agonist

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Myocardial Perfusion Imaging Adjunct	indication
Pericarditis	contraindication	3238004	DOID:1787
Bronchospasm	contraindication	4386001
Chronic obstructive lung disease	contraindication	13645005	DOID:3083
Disorder of autonomic nervous system	contraindication	15241006
Complete atrioventricular block	contraindication	27885002
Hypovolemia	contraindication	28560003
Acute cerebrovascular insufficiency	contraindication	29322000
Sick sinus syndrome	contraindication	36083008	DOID:13884
Hypertensive disorder	contraindication	38341003	DOID:10763
Low blood pressure	contraindication	45007003
Bradycardia	contraindication	48867003
Sinus bradycardia	contraindication	49710005
Wheezing	contraindication	56018004
Aortic valve stenosis	contraindication	60573004	DOID:1712
Carotid artery stenosis	contraindication	64586002	DOID:13001
Mitral valve stenosis	contraindication	79619009	DOID:1754
Seizure disorder	contraindication	128613002
Second degree atrioventricular block	contraindication	195042002
Asthma	contraindication	195967001	DOID:2841
Transient ischemic attack	contraindication	266257000	DOID:224
Syncope	contraindication	271594007
Left main coronary artery disease	contraindication	371804009
Pericardial effusion	contraindication	373945007	DOID:118

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	10.38	acidic
pKa2	11.67	acidic
pKa3	12.33	acidic
pKa4	13.34	acidic
pKa5	5.37	Basic
pKa6	4.79	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Adenosine receptor A2a	GPCR	P29274	AA2AR_HUMAN	AGONIST	EC50	5.89		WOMBAT-PK	CHEMBL
Adenosine receptor A1	GPCR	P30542	AA1R_HUMAN		EC50	4.40		WOMBAT-PK
Adenosine receptor A2a	GPCR		AA2AR_RAT		Ki	6.54		CHEMBL

External reference:

ID	Source
4027430	VUID
N0000176153	NUI
D05711	KEGG_DRUG
875148-45-1	SECONDARY_CAS_RN
4027430	VANDF
C0971703	UMLSCUI
CHEBI:135613	CHEBI
CHEMBL3989695	ChEMBL_ID
CHEMBL317052	ChEMBL_ID
DB06213	DRUGBANK_ID
C430916	MESH_SUPPLEMENTAL_RECORD_UI
219024	PUBCHEM_CID
5596	IUPHAR_LIGAND_ID
2XLN4Y044H	UNII
640062	RXNORM
136259	MMSL
25274	MMSL
d07131	MMSL
012689	NDDF
430242005	SNOMEDCT_US
433327005	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
LEXISCAN	HUMAN PRESCRIPTION DRUG LABEL	1	0469-6501	INJECTION, SOLUTION	0.08 mg	INTRAVENOUS	NDA	28 sections
LEXISCAN(R) (REGADENOSON)	HUMAN PRESCRIPTION DRUG LABEL	1	51662-1448	INJECTION, SOLUTION	0.08 mg	INTRAVENOUS	NDA	18 sections